Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment-free remission after sustained MR4.5 on nilotinib
2012-003186-18Phase 2Active
- Sponsor
- Novartis
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Nov 2012; status: active.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2012-003186-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003186-18.